SGLT2 inhibitors stimulate hepatic glucose production and also increase glucagon secretion, which promotes endogenous glucose production and restricts their glucose-lowering capacity [34]
Congress is still hashing out whether Medicare Part D should cover OK anti-obesity drugs, but coverage is limited
This dual action might lead to better results for certain individuals
Difficulty concentrating or "brain fog." When Weight Regain Suggests A Dosing Review Is Needed While some fluctuation in body weight is normal, a steady upward trend is a red flag
A person may experience clicking or popping of the jaw, jaw pain or headache, or trouble opening the mouth
Osteoarthritis, the most common form of joint disease, is strongly associated with obesity